1. Home
  2. MDWD vs BVFL Comparison

MDWD vs BVFL Comparison

Compare MDWD & BVFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • BVFL
  • Stock Information
  • Founded
  • MDWD 2000
  • BVFL 1873
  • Country
  • MDWD Israel
  • BVFL United States
  • Employees
  • MDWD N/A
  • BVFL N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • BVFL Savings Institutions
  • Sector
  • MDWD Health Care
  • BVFL Finance
  • Exchange
  • MDWD Nasdaq
  • BVFL Nasdaq
  • Market Cap
  • MDWD 208.2M
  • BVFL 150.2M
  • IPO Year
  • MDWD 2014
  • BVFL N/A
  • Fundamental
  • Price
  • MDWD $20.47
  • BVFL $15.63
  • Analyst Decision
  • MDWD Strong Buy
  • BVFL
  • Analyst Count
  • MDWD 2
  • BVFL 0
  • Target Price
  • MDWD $35.00
  • BVFL N/A
  • AVG Volume (30 Days)
  • MDWD 50.6K
  • BVFL 101.9K
  • Earning Date
  • MDWD 08-13-2025
  • BVFL 07-21-2025
  • Dividend Yield
  • MDWD N/A
  • BVFL N/A
  • EPS Growth
  • MDWD N/A
  • BVFL N/A
  • EPS
  • MDWD N/A
  • BVFL 1.06
  • Revenue
  • MDWD $19,213,000.00
  • BVFL $38,257,000.00
  • Revenue This Year
  • MDWD $20.80
  • BVFL N/A
  • Revenue Next Year
  • MDWD $26.92
  • BVFL N/A
  • P/E Ratio
  • MDWD N/A
  • BVFL $14.73
  • Revenue Growth
  • MDWD N/A
  • BVFL 1.89
  • 52 Week Low
  • MDWD $14.14
  • BVFL $12.50
  • 52 Week High
  • MDWD $22.51
  • BVFL $18.19
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.68
  • BVFL 67.45
  • Support Level
  • MDWD $19.07
  • BVFL $15.83
  • Resistance Level
  • MDWD $21.26
  • BVFL $16.10
  • Average True Range (ATR)
  • MDWD 0.69
  • BVFL 0.38
  • MACD
  • MDWD 0.12
  • BVFL 0.12
  • Stochastic Oscillator
  • MDWD 66.81
  • BVFL 86.98

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

Share on Social Networks: